Intersection · Compounds × randomised trial
Compounds topics tagged randomised trial
Topics in Compounds carrying the tag randomised trial. Randomised controlled trial evidence.
108 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?
Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Session topic: STEP 2 ( Lancet , 2021). Please read…
|
+43 | 47 | 5.5k | just now |
|
What TRIUMPH is designed to answer, and why we should not pre-empt it
What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…
|
+4 | 8 | 142 | 6h |
|
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…
|
2 | 17k | 6h | |
|
The SOUL trial and oral semaglutide cardiovascular outcomes
Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it…
|
2 | 7.1k | 9h | |
|
Molecular mass of semaglutide and why the figure differs between sources
Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…
|
+101 | 110 | 12k | 16h |
|
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
|
+10 | 14 | 8.4k | 16h |
|
What the GIP component of tirzepatide is thought to contribute, and how confident we can be
What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl…
|
+16 | 20 | 23k | 19h |
|
Why retatrutide discussion here is more cautious than elsewhere — one year on
Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…
|
+92 | 97 | 3.6k | 20h |
|
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…
|
+27 | 31 | 1.2k | 22h |
|
Historical amylin analogues and what happened to them
Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of a…
|
+29 | 36 | 31k | 1d |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile
Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. I have seen SCALE ( N Engl J Med…
|
+115 | 122 | 2.6k | 1d |
|
What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med…
|
+83 | 91 | 46k | 1d |
|
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…
|
+25 | 29 | 22k | 1d |
|
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
|
+19 | 23 | 16k | 2d |
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med…
|
+43 | 47 | 19k | 2d |
|
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a claim I do…
|
+14 | 18 | 10k | 2d |
|
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…
|
+5 | 9 | 30k | 8d |
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…
|
+17 | 21 | 17k | 12d |
|
Why fasting instructions for oral semaglutide are not optional advice
Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016)…
|
+70 | 74 | 1.1k | 23d |
|
Why oral semaglutide needs an absorption enhancer at all — one year on
Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…
|
+11 | 15 | 17k | 24d |
|
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…
|
+27 | 31 | 17k | 25d |
|
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SCALE ( N Engl J Med , 2015). Please read it…
|
+5 | 9 | 13k | 25d |
|
Does dual agonism explain the effect size, or is it dose?
Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…
|
+62 | 68 | 2.6k | 29d |
|
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N Engl J…
|
+23 | 27 | 9.9k | 1mo |
|
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J…
|
+109 | 122 | 3.6k | 2mo |
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 (…
|
+3 | 7 | 1k | 2mo |
|
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…
|
+7 | 12 | 7.7k | 2mo |
|
Oral semaglutide bioavailability and its variability between people
Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in…
|
+44 | 48 | 574 | 3mo |
|
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like
On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…
|
+41 | 46 | 1.2k | 4mo |
|
Why semaglutide solutions can look faintly opalescent and when that matters
The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…
|
+73 | 79 | 2k | 4mo |